Skip to main content
Premium Trial:

Request an Annual Quote

Anagnostics Gains CE-IVD Marks for Hybcell Array Sepsis, Drugs of Abuse Tests


Austrian molecular diagnostics firm Anagnostics said this week that it has received CE-IVD approval for two tests based on its Hybcell cylindrical microarray platform.

The first test, called Hybcell Fungi DNA PlexA, can be used to detect roughly a dozen fungi associated with sepsis. Anagnostics said the test can be used in combination with its Hybcell Bacteria DNA PlexA test, which attained a CE-IVD mark in October 2012, and "perfectly complements [our] product portfolio in the area of integrated sepsis diagnostics."

The St. Valentin-based company's Hybcell Fungi DNA PlexA assay has a turnaround time of four hours and is run in conjunction with Molzym's SepsiTest sample preparation kit and a combination of PCR and on-array compact sequencing to detect and quantify pathogens in a blood sample. Anagnostics announced its relationship with Bremen, Germany-based Molzym two years ago.

Anagnostics has also garnered a CE-IVD mark for its Hybcell DoA Urine PlexC test. The assay allows simultaneous testing of 23 drug groups using minimal amounts of urine and can provide a comprehensive report within 17 minutes.

The firm has amassed a number of CE-IVD-marked tests for use on its Hyborg instrument, including panels for BRAF and KRAS mutation detection, inflammation monitoring, and drugs of abuse. All of its assays are run using Anagnostics' Hybcell technology. While most commercially available arrays are printed on slides, Anagnostics prints its Hybcell arrays on cylinders that are processed automatically in sample containers by the Hyborg instrument.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.